Skip to main content
. 2020 Apr 7;111(5):1785–1793. doi: 10.1111/cas.14383

Figure 4.

Figure 4

Efficacy of curcumin, curcumin β‐D‐glucuronide (CMG) and L‐OHP on the KRASm/TP53w or KRASm/TP53‐ HCT116 xenograft model. A, Tumor‐bearing mice with KRASm/TP53w HCT116 cells were treated with curcumin, CMG, L‐OHP, and the combination of CMG and L‐OHP, as described in the Materials and Methods. Data represent means ± SD (n = 5‐6). *P < 0.05, as compared to the control group on day 21. B, Tumor‐bearing mice with KRASm/TP53‐ HCT116 cells were treated with CMG, L‐OHP, and the combination of CMG and L‐OHP, as described in the Materials and Methods. Data represent means ± SD (n = 7). *P < 0.05, as compared to the control group on day 21, #P < 0.05, as compared to the L‐OHP group on day 21